Skip to content


Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Can we relax yet?

Professor Peter J. Henning of Wayne State University Law School (Photo courtesy of Wayne Law)Over the last decade, since the passage of the Sarbanes-Oxley Act in 2002, publicly traded corporations have poured significant resources into their compliance programs to prevent wrongdoing, or to at least be an early warning system for what might become a problem. Companies know that it is always better to self-report a violation than to have a government agent come knocking on the door. [But that] buildup in corporate internal controls may lead to a false sense of security that the company will be able to ferret out internal wrongdoing before it burgeons into a serious concern. So there is often an urge to make the obligatory offer of the olive branch of cooperation when an accusation of wrongdoing arises accompanied by an assurance that the company had determined it did nothing wrong.

— From Lessons From the Glaxo Case in China by Peter J. Henning in the New York Times DealBook.

Share this post


Comments are closed for this article!